Peter Heinrich

Co-founder, Managing Director at Sinfonie LSM

Speaker

Over 20 years experience in research & development, drug development, licensing, new drug commercialization and business & corporate development, general management. Direct involvement in start-up ventures, publicly-held entities, strategic transactions, improving shareholder value, and mergers and acquisitions. His total transaction and deal volume exceeds € 1 billion. He is a co-founder of Sinfonie LSM and a co-founder and long year CEO of MediGene AG and also CEO of MagForce AG, both publicly traded companies. Prior to that, he was in the Biotechnology Department at Wacker Chemical, then a subsidiary of Hoechst AG. He studied biology and chemistry at Munich University where he received a PhD in biochemistry. After that he was a post-doc scientist for two years at Harvard University. He is the initiator, co-founder and Board member of BIO Deutschland, Germany´s Biotech industry organization for which he has served as its Chairman from 2004 -2019. He also serves on the Board of EuropaBio as Vice-Chairman and he was a previous member of the Board of the European Emerging Biopharmaceutical Enterprises (EBE), serving from 2003 – 2006 as EBE’s President. From 2014 – 2020 he was a Member of the Scientific Panel for Health (SPH) of the European Commission for Horizon 2020. Since 2006 he has been a member of the Board overseeing the Executive MBA Program at University of Augsburg. From 2016 – 2019 he was also member of the board of the Federation of German Industries (BDI), the voice of the German industry.

He is a serial entrepreneur and has started a number of Biotech companies in Europe, including Medigene, MediGenomix as well as he co-founded the leading immune oncology players Immunocore and Adaptimmune in Oxford, UK, for whom he served on the board for the first years after inception. He is currently chairman of the German Biotech company Syntab Therapeutics, chairman of the Swedish Biotech company Melius Pharma, and Board member of the US Medtech company Aijex Pharma International Inc.. In addition, he has been a member of the investment committee of the Scale-up Fund Bavaria since 2022, which can invest between € 10- 25 million in innovative start-ups.